What to use INSTEAD of inhaled corticosteroids in COPD?
نویسندگان
چکیده
منابع مشابه
What to use INSTEAD of inhaled corticosteroids in COPD?
Inhaled corticosteroids (ICS) have had an important impact on the management of chronic obstructive pulmonary disease (COPD). When combined with an inhaled long-acting b-agonist (LABA), they improve lung function more than is the case with the LABA alone, improve health status and reduce the number of exacerbations patients experience [1]. There are data to suggest that they modify the decline ...
متن کاملInhaled corticosteroids in COPD
C hronic obstructive pulmonary disease (COPD) is arguably the most common chronic disease of the lungs at present and, by 2020, it will be the third leading cause of death worldwide. COPD is associated with a relentless decline in forced expiratory volume in 1 second (FEV1) and, in the later stages, the condition progresses to pulmonary hypertension and hypoxic respiratory failure. Few interven...
متن کاملInhaled corticosteroids in COPD
The importance of presenting absolute cell numbers when counting cells in biological samples is illustrated by the potentially misleading interpretation of data in the paper by Marco Confalonieri and colleagues. The authors concluded that, in addition to reduced sputum neutrophilia, the number of sputum macrophages increased significantly following treatment with inhaled beclomethasone dipropio...
متن کاملArguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity.
Obviously, the guidelines are based on the best evidence available and studies such as ISOLDE showed that fluticasone (FLU) 500mg/12h was capable of significantly reducing exacerbations in patients with FEV1 <50%. 3 Concerning these results, two observations should be made: (a) the exacerbations were also reduced in patients with FEV1 >50%; in fact, the reduction was even greater, from 0.92 epi...
متن کاملInhaled Corticosteroids in COPD: A Controversy
Inhaled corticosteroids (ICS) are now very widely used in high doses in the management of COPD patients. In sharp contrast to the situation in asthma, ICS provide little or no benefit in COPD patients and may have long-term detrimental effects. High doses of ICS fail to reduce disease progression or mortality, even when combined with a long-acting 2 -agonist (LABA). Several trials have demonstr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2014
ISSN: 0903-1936,1399-3003
DOI: 10.1183/09031936.00181114